A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F-2 alpha analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin-timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (> 13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav(A (R)) (Alcon, Fort Worth, USA) and Ganfort(A (R)) (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.